108438-11-5

Basic information

• Product Name: 4-Chloro-3-Methoxyphenylisocyanate
• Synonyms: 4-Chloro-3-Methoxyphenylisocyanate
• CAS NO: 108438-11-5
• Molecular Formula: C₈H₆ClNO₂
• Molecular Weight: 183.59174
• Mol File: 108438-11-5.mol

Chemical Properties

• Boiling Point: 268.7±25.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4-Chloro-3-Methoxyphenylisocyanate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-3-Methoxyphenylisocyanate(108438-11-5)
• EPA Substance Registry System: 4-Chloro-3-Methoxyphenylisocyanate(108438-11-5)

Safety Data

• Hazardous Substances Data: 108438-11-5(Hazardous Substances Data)

Upstream product

• 154244-57-2 methyl N-(4-chloro-3-metyhoxyphenyl)carbamate 
• 108-46-3 recorcinol 

Downstream Products

• 23122-26-1 (4-Chloro-3-methoxy-phenyl)-carbamic acid 3-methoxycarbonylamino-phenyl ester 

Relevant articles and documents

Heterocyclic Substituted Acardite Derivate and Application Thereof

This present invention discloses a heterocyclic substituted acardite derivate and application thereof, namely compounds in the general formula (1) or the general formula (2) or pharmaceutically acceptable salts thereof, wherein A is monosubstituted or polysubstituted quinoline, isoquinoline, quinazoline, pyrrole or pyrimidine, and the substituent is halogen, C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, C1-5haloalkoxy, C1-5alkylamino, C1-5haloalkylamino, amino or nitryl; R1 is C1-5alkyl; R2 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; and R3 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy. The compound of the present invention and the pharmaceutically acceptable salt thereof can be used for treating tumor or leukemia.

HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF

The present invention discloses a heterocyclic substituted acardite derivate and application thereof, namely compounds of the general formula (1) or the general formula (2) or pharmaceutically acceptable salts thereof, wherein A is monosubstituted or polysubstituted quinoline, isoquinoline, quinazoline, pyrrole or pyrimidine, and the substituent is halogen, C1-5alkyl, C1-5haloalkyl, C1-5alkoxy, C1-5haloalkoxy, C1-5alkylamino, C1-5haloalkylamino, amino or nitryl; R1 is C1-5alkyl; R2 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy; and R3 is one or more selected from hydrogen, halogen, alkyl, alkoxy, haloalkyl or haloalkoxy. The compound of the present invention and the pharmaceutically acceptable salt thereof can be used for treating tumor or leukemia.

Thermolysis of Alkyl N-Phenylcarbamates in the Presence of Hydroxy Compounds

Kinetic and activation parameters of thermolysis of alkyl N-phenylcarbamates in the presence of hydroxy compounds in diglyme are determined. Hydroxy compounds accelerate thermolysis of carbamates. The initial stage of the reaction in the presence of alcohols and phenols is formation of a complex of carbamate with the hydroxy compound. The compositions of the complexes are determined thermochemically, and the stability constants and enthalpies of formation are calculated.